PTW Freiburg VERIQA RT MonteCarlo 3D v3 software recalled for unclear bolus display in dose calculations
The VERIQA RT MonteCarlo 3D v3 radiation therapy planning software includes bolus (a material placed on the skin to modify radiation dose) in dose calculations, but does not clearly display that the bolus is accounted for. This may cause treatment staff to accidentally skip the bolus during treatment, leading to radiation being delivered to the wrong tissue depth.
From the FDA notice · Read the official notice ↗
What to do
- If you use this software version (3.1.18, Model S070031.520), verify that any bolus is visually confirmed before each treatment.
- Contact PTW Freiburg or your radiation oncology supervisor for guidance on secondary dose calculations involving bolus.
- Check with the manufacturer for a software update or corrective instructions.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Brand Name: VERIQA; Product Name: RT MonteCarlo 3D v3; Model/Catalog Number: S070031.520; Software Version: 3.1.18;
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
Details
- Units affected
- 2
- Illnesses reported
- None reported
- Manufactured in
- Lorracher Str. 7, N/A, Freiburg Im Breisgau, N/A, Germany
- Classification
- Class II
- Recall number
- Z-3174-2026
In the FDA's words
- Description
- Brand Name: VERIQA; Product Name: RT MonteCarlo 3D v3; Model/Catalog Number: S070031.520; Software Version: 3.1.18; When a bolus is included in a treatment plan and sent for secondary dose calculation, the software accounts for it but does not display this clearly, which may lead users to incorrectly omit the bolus during treatment and deliver the prescribed dose to the wrong tissue depth. Model/Catalog Number: S070031.520; UDI-DI: +EPTWS070031Q5200; Software Version 3.1.18; Distribution: Worldwide - US Nationwide distribution in the states of GA, NY and the countries of Austria, Belgium, Switzerland, Czechia, Germany, Spain, France, Netherlands, Norway, Poland, Portugal, Romania, T¿rkiye, Chile, United Arab Emirates, Saudi Arabia, Mexico, Hong Kong, Brazil, Tajikistan, Ecuador, Iran, Thailand, Serbia, South Africa, Kazakhstan, Algeria. Affected quantity: 2
- Hazard
- When a bolus is included in a treatment plan and sent for secondary dose calculation, the software accounts for it but does not display this clearly, which may lead users to incorrectly omit the bolus during treatment and deliver the prescribed dose to the wrong tissue depth.